Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

키워드

참고문헌 (86)

1. Thommen DS, "T cell dysfunction in cancer", Cancer Cell, 33, pp.547~562 (2018)
2. Chen DS, "Oncology meets immuno-logy : the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
3. Ribas A, "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
4. Gibney GT, "Predictive biomarkers for checkpoint inhibitor-based immunotherapy", Lancet Oncol, 17, pp.e542~e551 (2016)
5. Zaretsky JM, "Muta-tions associated with acquired resistance to PD-1 blockade in melanoma", N Engl J Med, 375, pp.819~829 (2016)
6. Kong X, "Discovery of new immune checkpoints : family grows up", Adv Exp Med Biol, 1248, pp.61~82 (2018)
7. Rotte A, "Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy", Ann Oncol, 29, pp.71~83 (2018)
8. Chan CJ, "Receptors that interact with nectin and nectin-like proteins in the immu-nosurveillance and immunotherapy of cancer", Curr Opin Immunol, 24, pp.246~251 (2012)
9. Sanchez-Correa B, "DNAM-1 and the TIGIT", PVRIG, Cancers (Basel), pp.2019, 11[DOI]
10. Whelan S, "PVRIG and PVRL2 are induced in cancer and inhibit CD8(+)T-cell function", Cancer Immunol Res, 7, pp.257~268 (2019)
11. Marin-Acevedo JA, "Cancer immunotherapy beyond immune checkpoint inhibitors", J Hematol Oncol, 11, pp.8~ (2006)
12. Gorvel L, "Targeting the"PVR-TIGIT axis"with immune checkpoint therapies", F1000Res, 9 (2020)
13. Fuchs A, "The role of NK cell recognition of nectin and nectin-like proteins in tumor immuno-surveillance", Semin Cancer Biol, 16, pp.359~366 (2006)
14. Nakanishi H, "Roles of nectins in cell adhe-sion, migration and polarization", Biol Chem, 385, pp.885~892 (2004)
15. Zhang Q, "Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity", Nat Immunol, 19, pp.723~732 (2018)
16. Kucan Brlic P, "Targeting PVR(CD155)and its receptors in anti-tumor therapy", Cell Mol Immunol, 16, pp.40~52 (2019)
17. Nishiwada S, "Clinical significance of CD155 expression in human pancreatic cancer", Anticancer Res, 35, pp.2287~2297 (2015)
18. Triki H, "CD155 expression in human breast cancer : clinical significance and rele-vance to natural killer cell infiltration", Life Sci, 231, pp.116543~ (2019)
19. Carlsten M, "Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells", J Immunol, 183, pp.4921~4930 (2009)
20. Joller N, "Cutting edge : TIGIT has T cell-intrinsic inhibitory functions", J Immunol, 186, pp.1338~1342 (2011)
21. Fuchs A, "Cutting edge : CD96(tactile)promotes NK cell-target cell adhesion by interacting with the poliovirus receptor(CD155)", J Immunol, 172, pp.3994~3998 (2004)
22. Yu X, "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells", Nat Immunol, 10, pp.48~57 (2009)
23. Stanietsky N, "Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR", Eur J Immunol, 43, pp.2138~2150 (2013)
24. Deuss FA, "Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155", Structure, 27, pp.219~228 (2019)
25. Okumura G, "Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells", J Exp Med, 217, pp.1~ (2020)
26. Weulersse M, "Eomes-dependent loss of the co-activating receptor CD226 re-strains CD8(+)T cell anti-tumor functions and limits the effi-cacy of cancer immunotherapy", Immunity, 53, pp.824~839 (2020)
27. Zhu Y, "Identification of CD112R as a novel checkpoint for human T cells", J Exp Med, 213, pp.167~176 (2016)
28. Pende D, "Expression of the DNAM-1 ligands, nectin-2(CD112)and poliovirus receptor(CD155), on dendritic cells : relevance for natural killer-dendritic cell interaction", Blood, 107, pp.2030~2036 (2006)
29. Seth S, "The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1", Biochem Biophys Res Commun, 364, pp.959~965 (2007)
30. Satoh-Horikawa K, "Nectin-3, a new member of immunoglobulin-like cell adhe-sion molecules that shows homophilic and heterophilic cell-cell adhesion activities", J Biol Chem, 275, pp.10291~10299 (2000)
31. Reches A, "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity", J Immunother Cancer, (8), pp.e000266~ (2020)
32. Harjunpaa H, "TIGIT as an emerging immune checkpoint", Clin Exp Immunol, 200, pp.108~119 (2020)
33. Lozano E, "The TIGIT", CD226 axis regulates human T cell func-tion, 2012, pp.188, 3869~3875
34. Johnston RJ, "The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+)T cell effector function", Cancer Cell, 26, pp.923~937 (2014)
35. Joller N, "Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses", Immunity, 40, pp.569~581 (2014)
36. Kurtulus S, "TIGIT predominantly regulates the immune response via regu-latory T cells", J Clin Invest, 125, pp.4053~4062 (2015)
37. Yang ZZ, "TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in folli-cular lymphoma", Clin Cancer Res, 26, pp.5217~5231 (2020)
38. Kong Y, "T-cell immuno-globulin and ITIM domain(TIGIT)associates with CD8+T-cell exhaustion and poor clinical outcome in AML pa-tients", Clin Cancer Res, 22, pp.3057~3066 (2016)
39. Chauvin JM, "TIGIT and PD-1 impair tumor antigen-specific CD8(+)T cells in melanoma patients", J Clin Invest 125 (2015)
40. Guillerey C, "TIGIT immune checkpoint blockade restores CD8(+)T-cell im-munity against multiple myeloma", Blood, 132, pp.1689~1694 (2018)
41. He W, "CD155T", TIGIT sig-naling regulates CD8(+)T-cell metabolism and promotes tumor progression in human gastric cancer, 2017, pp.77, 6375~6388
42. O’Brien SM, "Function of human tumor-infiltrating lymphocytes in earlystage non-small cell lung cancer", Cancer Immunol Res, 7, pp.896~909 (2019)
43. Ostroumov D, "Transcriptome profiling identifies TIGIT as a marker of T cell exhaustion in liver cancer", Hepatology (2020)
44. Stalhammar G, "Ex-pression of immune checkpoint receptors Indoleamine 2, 3-dioxygenase and T cell Ig and ITIM domain in meta-static versus nonmetastatic choroidal melanoma", Cancer Med, 8, pp.2784~2792 (2019)
45. Xu D, "TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer", Immunobiology, 225, pp.151915~ (2020)
46. Wu L, "Blockade of TIGIT", CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma, 2019, pp.7, 1700~1713
47. Lucca LE, "Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS", Neurol Neuroimmunol Neuroinflamm, 7, pp.e712~ (2020)
48. Jin HS, "CD226(hi)CD8(+)T cells are a prerequisite for anti-TIGIT immunotherapy", Cancer Immunol Res, 8, pp.912~925 (2020)
49. McLane LM, "CD8 T cell exhaustion during chronic viral infection and cancer", Annu Rev Immunol, 37, pp.457~495 (2019)
50. Hashimoto M, "CD8 T cell exhaustion in chronic infection and cancer : oppor-tunities for interventions", Annu Rev Med, 69, pp.301~318 (2018)
51. Tang W, "Clinical significance of CD8(+)T cell immunoreceptor with Ig and ITIM domains(+)in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy", Oncoimmunology, 8, pp.e1593807~ (2019)
52. Fuhrman CA, "Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226", J Immunol, 195, pp.145~155 (2015)
53. Duan X, "Expression of TIGIT", CD155 and correlations with clinical pathological features in human hepatocellular carcinoma, 2019, pp.20, 3773~3781
54. Fourcade J, "CD226 opposes TIGIT to disrupt Tregs in melanoma", JCI Insight, 3, pp.e121157~ (2018)
55. Dixon KO, "Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity", J Immunol, 200, pp.3000~3007 (2018)
56. Chiu DK, "Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing poliovirus receptor and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice", Gastroenterology, 159, pp.609~623 (2020)
57. Lee BR, "Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade", JCI Insight, 5, pp.e128633~ (2020)
58. Jin HS, "Extracellular pH modulating injectable gel for enhancing immune check-point inhibitor therapy", J Control Release, 315, pp.65~75 (2019)
59. Hung AL, "TIGIT and PD-1 dual checkpoint blockade enhances antitumor immu-nity and survival in GBM", Oncoimmunology, 7, pp.e1466769~ (2018)
60. Grapin M, "Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT : a promising new combination", J Immunother Cancer, 7, pp.160~ (2019)
61. Wang B, "Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+)T cell dysfunction and maintain memory phenotype", Sci Immunol, 3, pp.eaat7061~ (2018)
62. Liu S, "Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells", Cell Death Differ, 20, pp.456~464 (2013)
63. Shibuya K, "Physical and functional association of LFA-1 with DNAM-1 adhesion molecule", Immunity, 11, pp.615~623 (1999)
64. Enqvist M, "Coordinated expression of DNAM-1 and LFA-1 in educated NK cells", J Immunol, 194, pp.4518~4527 (2015)
65. Shibuya A, "DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes", Immunity, 4, pp.573~581 (1996)
66. Iguchi-Manaka A, "Accele-rated tumor growth in mice deficient in DNAM-1 receptor", J Exp Med, 205, pp.2959~2964 (2008)
67. Sanchez-Correa B, "Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients", Immunol Cell Biol, 90, pp.109~115 (2012)
68. Minnie SA, "Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade", Blood, 132, pp.1675~1688 (2018)
69. Jin Z, "Higher TIGIT(+)CD226(-)gammadelta T cells in patients with acute myeloid leuke-mia", Immunol Invest, pp.1~11 (2020)
70. Gilfillan S, "DNAM-1promotes activation of cytotoxic lymphocytes by nonpro-fessional antigen-presenting cells and tumors", J Exp Med, 205, pp.2965~2973 (2008)
71. Chan CJ, "The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions", Nat Immunol, 15, pp.431~438 (2014)
72. Lakshmikanth T, "NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo", J Clin Invest, 119, pp.1251~1263 (2009)
73. Zhang Z, "DNAM-1 controls NK cell activation via an ITT-like motif", J Exp Med, 212, pp.2165~2182 (2015)
74. Braun M, "CD155on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226in CD8(+)T cells", Immunity, 53, pp.805~823 (2020)
75. Georgiev H, "Coming of age : CD96 emerges as modulator of immune responses", Front Immunol, 9, pp.1072~ (2018)
76. Lepletier A, "The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells", Immunol Cell Biol, 97, pp.152~164 (2019)
77. Mittal D, "CD96 is an immune checkpoint that regulates CD8(+)T-cell antitumor function", Cancer Immunol Res, 7, pp.559~571 (2019)
78. Sun H, "Human CD96correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma", Hepatology, 70, pp.168~183 (2019)
79. Peng YP, "Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer", Oncotarget, 7, pp.66586~66594 (2016)
80. Blake SJ, "Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy", Cancer Discov, 6, pp.446~459 (2016)
81. Chiang EY, "CD96 functions as a co-stimulatory receptor to enhance CD8(+)T cell activation and effector responses", Eur J Immunol, 50, pp.891~902 (2020)
82. Meyer D, "CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains", J Biol Chem, 284, pp.2235~2244 (2009)
83. Chambers CA, "The expanding world of co-stimula-tion : the two-signal model revisited", Trends Immunol, 22, pp.217~223 (2001)
84. Roman Aguilera A, "CD96targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity", Onco-immunology, 7, pp.e1424677~ (2018)
85. Murter B, "Mouse PVRIG has CD8(+)T cell-specific coinhibitory functions and dampens antitumor immunity", Cancer Immunol Res, 7, pp.244~256 (2019)
86. Xu F, "Blockade of CD112R and TIGIT signaling sensi-tizes human natural killer cell functions", Cancer Immunol Immunother, 66, pp.1367~1375 (2017)

관련 논문AI추천